Retina Associates of Cleveland — Cleveland, Ohio

Retina Associates of Cleveland is a clinical research site located in Cleveland, Ohio, United States 44122.

Crixeo Clinical Trials Trust Score: 25/100 (FAILING). This profile has not yet been claimed by the site owner.

Retina Associates of Cleveland has participated in 35 clinical trials with 12 currently active.

Therapeutic areas: Macular Telangiectasia Type 2 (MacTel), Macular Neovascularization Secondary to Age-Related Macular Degeneration, Geographic Atrophy.

Sponsors: The Lowy Medical Research Institute Limited, 4D Molecular Therapeutics, Neurotech Pharmaceuticals.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Cleveland

Browse all research sites in Ohio · View every site in Cleveland

Sponsor Feasibility Report

Trust Score: 25/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Retina Associates of Cleveland?

Retina Associates of Cleveland has a Crixeo Trust Score of 25/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Retina Associates of Cleveland conducted?

Retina Associates of Cleveland has 35 clinical trials on record, with 12 currently active. Their work covers Macular Telangiectasia Type 2 (MacTel), Macular Neovascularization Secondary to Age-Related Macular Degeneration, Geographic Atrophy.

Is Retina Associates of Cleveland accredited by Crixeo Clinical Trials?

Retina Associates of Cleveland has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Retina Associates of Cleveland?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.